

CITATION REPORT

List of articles citing

Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group

DOI: 10.1001/jama.281.5.421

JAMA - Journal of the American Medical Association, 1999, 281, 421-6.

Source: <https://exaly.com/paper-pdf/30169661/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
484	Sildenafil. 1999 , 1, 137-47		16
483	Male impotence. 1999 , 354, 1713-8		66
482	Sildenafil (Viagra) and ophthalmology. 1999 , 44, 153-62		136
481	Oral pharmacotherapy for erectile dysfunction: current perspectives. 1999 , 54, 392-400		21
480	Pharmacotherapeutic advances in the treatment of erectile dysfunction. 1999 , 74, 709-21		43
479	Erectile dysfunction in the aging man. 1999 , 83, 1267-78		22
478	[Our clinical experience with the use of ++sildenafil citrate to treat erectile dysfunction]. 1999 , 23, 859-63		2
477	Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. <i>Journal of Urology</i> , 1999 , 162, 1992-7; discussion 1997-8	2.5	75
476	Sildenafil: a review of its use in erectile dysfunction. 1999 , 57, 967-89		138
475	Sildenafil and sexual dysfunction associated with antidepressants. 1999 , 25, 259-64		9
474	Literature update: A critical review. 1999 , 14, 405-412		1
473	Erectile dysfunction in patients with diabetes. 1999 , 60, 638-44		28
472	Non-surgical management of erectile dysfunction. 2000 , 52, 253-60		16
471	Introduction. 2000 , 86, 1-2		2
470	Oral and injectable medications for the treatment of erectile dysfunction. 2000 , 1, 307-12		6
469	sildenafil, erectielsildenafil, diabetesSildenafil: de oplossing voor mannelijke diabetes, sildenafilidiabetespatiënten met erectie, sildenafilerectiele disfunctie?. 2000 , 38, 26-26		
468	Incidence of erectile dysfunction after open abdominal aortic aneurysm repair. 2000 , 14, 13-9		37

- 467 Erectile dysfunction. **2000**, 11, 29-35
- 466 Acute, Symptomatic Atrial Fibrillation after Sildenafil Citrate Therapy in a Patient with Hypertrophic Obstructive Cardiomyopathy. *American Journal of the Medical Sciences*, **2000**, 320, 69-71 2.2 6
- 465 Sildenafil: a urologist's view. **2000**, 16 Suppl 1, s48-58 4
- 464 Side-effect profile of sildenafil citrate (Viagra) in clinical practice. **2000**, 56, 474-6 111
- 463 Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members. **2000**, 17, 77-107 36
- 462 REDUCTION OF ENDOTHELIAL AND SMOOTH MUSCLE DENSITY IN THE CORPORA CAVERNOSA OF THE STREPTOZOTOCIN INDUCED DIABETIC RAT. *Journal of Urology*, **2000**, 164, 1807-1811 2.5 71
- 461 A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction. **2001**, 24, 255-65 3
- 460 Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. **2001**, 16, 1818-22 72
- 459 Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. **2001**, 283, 923-7 181
- 458 Sildenafil citrate: a therapeutic update. **2001**, 23, 2-23 65
- 457 Neurologic erectile dysfunction. **2001**, 28, 289-308 54
- 456 Oral drug therapy for erectile dysfunction. **2001**, 28, 321-34 71
- 455 LONG-TERM EFFICACY OF SILDENAFIL AND TACHYPHYLAXIS EFFECT. *Journal of Urology*, **2001**, 166, 927-931 2.5 80
- 454 Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of alprostadil. **2001**, 24, 409-11 13
- 453 CORPOREAL STRUCTURAL AND VASCULAR MICRO ARCHITECTURE WITH X-RAY MICRO COMPUTERIZED TOMOGRAPHY IN NORMAL AND DIABETIC RABBITS: HISTOPATHOLOGICAL CORRELATION. *Journal of Urology*, **2001**, 165, 1776-1782 2.5 36
- 452 Complicaciones de la diabetes mellitus. Diagnóstico y tratamiento. **2001**, 27, 132-145 3
- 451 [Results after treatment with sildenafil citrate in 100 patients with erectile dysfunction]. **2001**, 25, 335-40
- 450 Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. **2001**, 178, 325-30 22

449	Erectile Dysfunction in Chronic Peritoneal Dialysis Patients: Incidence and Treatment with Sildenafil. 2001 , 21, 355-359	16
448	Diabetic Neuropathies. 2001 , 12, 307-320	11
447	Familial amyloid polyneuropathy: presentation, diagnosis, and treatment. 2001 , 2, 221-6	2
446	Sexual aspects of headache. How sexual function relates to headaches and their causes and treatment. 2001 , 109, 81-4, 87-8, 92	7
445	AUTONOMIC DISORDERS. 2001 , 7, 220-233	5
444	Treatments for diabetic neuropathy. 2001 , 1, 127-32	14
443	The interface of psychiatric disorders and diabetes mellitus. 2001 , 3, 243-50	4
442	Neurogenic erectile dysfunction. 2001 , 11, 285-94	13
441	Sildenafil inhibits gastroduodenal motility. 2001 , 15, 157-61	29
440	Efficacy of apomorphine SL in erectile dysfunction. 2001 , 88 Suppl 3, 25-9	24
439	Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. 2001 , 88, 241-3	20
438	Neurosexology. 2001 , 8, 2-24	31
437	Evaluation of side effects of sildenafil in group of young healthy volunteers. 2001 , 32, 705-8	12
436	Sildenafil test: changes in the diagnostic and therapeutic management of erectile dysfunction. 2001 , 33, 387-9	6
435	Efficacy results and quality-of-life measures in men receiving sildenafil citrate for the treatment of erectile dysfunction. 2001 , 10, 359-69	63
434	Effects of sildenafil on esophageal motility of normal subjects. 2001 , 46, 2301-6	31
433	Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. 2001 , 133, 455-8	80
432	The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. 2001 , 425, 57-64	48

431	Is the sildenafil product information adequate to facilitate informed therapeutic decisions?. 2001 , 35, 337-42	
430	New techniques for the evaluation of diabetic neuropathies. 2001 , 3, 1-8	
429	Effect of sildenafil on ocular haemodynamics. 2001 , 15, 507-10	40
428	MUSE: clinical experience. 2002 , 18, 64-7	8
427	Effects of tadalafil on erectile dysfunction in men with diabetes. 2002 , 25, 2159-64	206
426	Sildenafil citrate in the management of diabetic erectile dysfunction. 2002 , 2, 306-308	
425	Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. 2002 , 25, 1336-9	207
424	Human and rabbit cavernosal smooth muscle cells express Rho-kinase. 2002 , 14, 1-7	78
423	Outcome measures for erectile dysfunction 2: evaluation. 2002 , 11, 120-5	1
422	Outcome measures for erectile dysfunction. 1: Literature review. 2002 , 11, 54-64	4
421	Erectile dysfunction in patients with diabetes mellitus Advances in treatment with phosphodiesterase type 5 inhibitors. 2002 , 2, 282-287	8
420	Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. 2002 , 25, 284-91	229
419	The hemodynamics of erection and the pharmacotherapies of erectile dysfunction. 2002 , 4, 252-64	5
418	Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. 2002 , 77, 276-82	46
417	Management of Erectile Dysfunction. 2002 , 10, 431-452	5
416	[Erectile dysfunction]. 2002 , 26, 667-90	5
415	[Efficacy and safety of sildenafil in patients with erectile dysfunction and hypertension. Prognostic factors]. 2002 , 119, 281-5	4
414	Current oral treatments for erectile dysfunction. 2002 , 3, 1613-29	8

413	Introduction. The management of erectile dysfunction (ED). 2002 , 60, 1-3	4
412	The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. 2002 , 60, 12-27	130
411	Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. 2002 , 60, 49-57	49
410	Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. 2002 , 60, 58-66	58
409	[Efficacy and safety of sildenafil in men with type 2 diabetes mellitus and erectile dysfunction]. 2002 , 119, 121-4	8
408	Endocrine abnormalities in chronic renal failure. 2002 , 31, 107-19	40
407	Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. 2002 , 67, 20-8	67
406	Erectile dysfunction and diabetes. 2002 , 2, 60-6	19
405	Combination therapy for erectile dysfunction: where we are and what's in the future. 2002 , 3, 467-70	11
404	Onset and duration of action of sildenafil for the treatment of erectile dysfunction. 2002 , 53 Suppl 1, 61S-65S	68
403	The clinical studies of sildenafil for the ageing male. 2002 , 25, 28-33	21
402	Early introduction of an evidence-based medicine course to preclinical medical students. 2002 , 17, 58-65	55
401	Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. 2002 , 2, 6	28
400	Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients. 2002 , 9, 308-15	16
399	The International Index of Erectile Function (IIEF): a state-of-the-science review. 2002 , 14, 226-44	718
398	Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. 2002 , 14, 466-71	84
397	Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. 2002 , 137, 295-310	134
396	The clinical safety of viagra. 2002 , 962, 378-88	33

395	Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. 2003 , 48, 2064-8		23
394	[How effective are PDE-5 inhibitors?]. 2003 , 42, 553-8		4
393	Diagnosis and management of diabetic autonomic neuropathy. <i>Comprehensive Therapy</i> , 2003 , 29, 130-45		18
392	Cavernosal tissue nitrite, nitrate, malondialdehyde and glutathione levels in diabetic and non-diabetic erectile dysfunction. 2003 , 26, 250-4		30
391	Premature ejaculation in non-insulin-dependent diabetic patients. 2003 , 26, 329-34		56
390	A baseline-controlled, open-label, flexible dose-escalation study to assess the safety and efficacy of sildenafil citrate (Viagra) in patients with erectile dysfunction. 2003 , 15 Suppl 1, S19-24		11
389	Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. 2003 , 15 Suppl 1, S25-9		20
388	Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. 2003 , 15, 347-54		47
387	Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. 2003 , 26, 279-84		124
386	Erectile dysfunction risk factors in noninsulin dependent diabetic Saudi patients. <i>Journal of Urology</i> , 2003 , 169, 1043-7	2.5	64
385	Optimizing treatment for diabetes mellitus induced erectile dysfunction. <i>Journal of Urology</i> , 2003 , 170, S35-8; discussion S39	2.5	45
384	Implications of diabetes mellitus in urology. 2003 , 30, 1-12		70
383	Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. <i>Journal of Urology</i> , 2003 , 169, 1999-2007	2.5	82
382	Erectile dysfunction in early, middle, and late adulthood: symptom patterns and psychosocial correlates. 2003 , 29, 381-99		33
381	Cardiovascular safety of sildenafil. 2003 , 26, 453-60		14
380	Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. 2003 , 312, 1202-8		89
379	Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62		77
378	Penile axial rigidity and Doppler ultrasonography parameters in patients with erectile dysfunction: association with type 2 diabetes. 2003 , 62, 525-31		18

377	Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. 2003 , 62, 121-5; discussion 125-6		250
376	BAY41-2272, a Novel Nitric Oxide Independent Soluble Guanylate Cyclase Activator, Relaxes Human and Rabbit Corpus Cavernosum In Vitro. <i>Journal of Urology</i> , 2003 , 169, 761-766	2.5	53
375	Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. 2003 , 26, 777-83		292
374	Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: a common defect?. 2003 , 1, 75-80		20
373	Phosphodiesterase type 5 (PDE5) inhibitors. 2003 , 41, 249-306		23
372	Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. 2003 , 26, 1093-9		164
371	Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. 2003 , 6, 94-99		138
370	Cialis (tadalafil): a new treatment for erectile dysfunction. 2003 , 64, 589-92		2
369	Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 56-64	27.4	148
368	Cognitive changes predict continued recovery of erectile functioning versus relapse after discontinuation of sildenafil treatment for male erectile dysfunction. 2003 , 65, 709-18		20
367	Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. 2003 , 9, 52-63		10
366	Erectile Dysfunction in the Elderly: Epidemiology, Etiology, and Approaches to Treatment. 2004 , 241-254		1
365	Erectile dysfunction after open versus angioplasty aortoiliac procedures: a questionnaire survey. 2004 , 38, 157-65		16
364	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. 2004 , 17, 239-250		1
363	Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. 2004 , 94, 1301-9		59
362	The female partner's satisfaction with sildenafil citrate treatment of erectile dysfunction. 2004 , 11, 755-62		25
361	Update on oral treatments for male erectile dysfunction. 2004 , 18, 267-74		25
360	Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. 2004 , 16, 21-9		62

359	NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. 2004 , 16, 195-200	20
358	Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. 2004 , 16, 135-42	67
357	A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. 2004 , 16, 479-85	20
356	Specific aspects of erectile dysfunction in endocrinology. 2004 , 16 Suppl 2, S10-2	10
355	Core document on erectile dysfunction: key aspects in the care of a patient with erectile dysfunction. 2004 , 16 Suppl 2, S26-39	16
354	Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. 2004 , 1, 292-300	95
353	Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. 2004 , 18, 205-10	49
352	Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. 2004 , 46, 73-9	30
351	Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. 2004 , 46, 503-9	32
350	The influence of sildenafil on random skin flap survival in rats: an experimental study. 2004 , 57, 769-72	75
349	Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient. 2004 , 23, 125-9	14
348	Therapy of ED: PDE-5 Inhibitors. 2004 , 23, 135-41	24
347	Therapy of erectile dysfunction: potential future treatments. 2004 , 23, 167-76	19
346	Population dose-response model for tadalafil in the treatment of male erectile dysfunction. 2004 , 21, 1463-70	10
345	Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. 2004 , 27, 114-19	49
344	[Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy]. 2004 , 43, 197-207; quiz 208-9	3
343	Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. 2004 , 47, 1914-23	132
342	Diabetes and erectile dysfunction. 2004 , 1, 87-91	2

341	Erectile dysfunction and cardiovascular disease. 2004 , 79, 782-94	14
340	Erectile dysfunction: etiology, evaluation, and treatment options. 2004 , 88, 387-416, xi	8
339	Diabetic neuropathies. 2004 , 88, 947-99, xi	182
338	Gonadal and erectile dysfunction in diabetics. 2004 , 88, 933-45, xi	10
337	New phosphodiesterase inhibitors in the treatment of erectile dysfunction. 2004 , 5, 2241-9	11
336	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88	69
335	Future options for combination therapy in the management of erectile dysfunction in older men. 2004 , 21, 555-64	26
334	Evidence-based endocrinology: how far have we come?. 2004 , 3, 1-10	7
333	The discovery and development of Viagra [®] (sildenafil citrate). 2004 , 1-13	4
332	Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis. 2004 , 2, 56-63	17
331	Elevation of intracavernous pressure and NO-cGMP activity by a new herbal formula in penile tissues of aged and diabetic rats. 2004 , 94, 85-92	34
330	Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. 2004 , 25, 830-6	115
329	Erectile Dysfunction and Cardiovascular Disease. 2004 , 79, 782-794	49
328	Understanding erectile dysfunction medication preference studies. 2004 , 14, 367-73	30
327	Association between the Erectile Dysfunction Inventory of Treatment Satisfaction and the Self-Esteem and Relationship Questionnaire following treatment with sildenafil citrate for men with erectile dysfunction. 2005 , 8 Suppl 1, S54-60	22
326	Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. 2005 , 95, 890-4	31
325	Phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 96, 257-80	153
324	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. 2005 , 96, 1323-32	78

323	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). 2005 , 59, 680-91	61
322	A study of the management of erectile dysfunction in general practice. 2005 , 30, 297-304	
321	Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. 2005 , 17, 80-5	19
320	The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. 2005 , 17, 134-41	46
319	Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. 2005 , 17, 264-9	17
318	Efficacy of sildenafil as the first-step therapeutic tool for Japanese patients with erectile dysfunction. 2005 , 17, 339-42	4
317	Gene and stem cell therapy for erectile dysfunction. 2005 , 17 Suppl 1, S57-63	23
316	Effect of diabetes on the mechanisms of intrathecal antinociception of sildenafil in rats. 2005 , 527, 60-70	31
315	The efficacy and safety of PDE5 inhibitors. 2005 , 7, 47-56	28
314	A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. 2005 , 2, 53-7	20
313	Sildenafil citrate response correlates with the nature and the severity of penile vascular insufficiency. 2005 , 2, 104-8	24
312	Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. 2005 , 2, 341-6	26
311	Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. 2005 , 2, 415-25; discussion 425-7	80
310	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. 2005 , 23, 374-84	25
309	Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. 2005 , 5, 18	43
308	A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. 2005 , 76, 700-5	90
307	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 2, 239-47	40
306	Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. 2005 , 51, 15-31	23

305	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. 2005 , 1, 283-93	34
304	Disfunci3n er3ctil: objetivos e intervenciones en la consulta de enfermer3a. 2005 , 15, 43-49	0
303	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. 2005 , 32, 419-29, vi	34
302	Central nervous system agents in the treatment of erectile dysfunction. 2005 , 32, 487-501, vii	6
301	Therapy Insight: sexual and bladder dysfunction associated with diabetes mellitus. 2005 , 2, 282-90; quiz 309	38
300	Phosphodiesterase 5 inhibitors for erectile dysfunction. 2005 , 39, 1286-95	61
299	Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis. 2005 , 27, 1452-61	13
298	Prevalence and risk factors for erectile dysfunction in Japanese diabetics. 2005 , 70, 81-9	57
297	Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. 2005 , 65, 755-9	35
296	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. 2005 , 65, 1621-50	133
295	PDE-5 inhibitors: current status and future trends. 2005 , 32, 511-25, viii	25
294	Safety and tolerability of oral erectile dysfunction treatments in the elderly. 2005 , 22, 323-38	5
293	Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. 2006 , 22, 2111-20	24
292	Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. 2006 , 13, 705-15	73
291	Sexual problems in diabetes. 2006 , 34, 99-100	
290	Diabetic uropathy. 2006 , 26, 182-5	49
289	Efficacy of sildenafil citrate in treatment of erectile dysfunction: impact of associated premature ejaculation and low desire. 2006 , 68, 642-7	17
288	Erection hardness: a unifying factor for defining response in the treatment of erectile dysfunction. 2006 , 68, 17-25	53

287	Research instruments for the diagnosis and treatment of patients with erectile dysfunction. 2006 , 68, 6-16		46
286	Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). 2006 , 68, 26-37		41
285	Erectile and sexual dysfunction in the aging diabetic male. 2006 , 2, 1025-1034		2
284	The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. 2006 , 23, 873-8		48
283	Comparison of phosphodiesterase type 5 (PDE5) inhibitors. 2006 , 60, 967-75		113
282	Pathophysiology and treatment of diabetic erectile dysfunction. <i>Asian Journal of Andrology</i> , 2006 , 8, 675-84	2.8	88
281	Infection induced inflammation is associated with erectile dysfunction in men with diabetes. 2006 , 36, 497-502		20
280	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702		366
279	Effect of sildenafil on ocular hemodynamics in 3 months regular use. 2006 , 18, 282-6		17
278	Association between comorbidity and erectile dysfunction in patients with diabetes. 2006 , 18, 348-53		20
277	Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. 2006 , 18, 550-8		17
276	Vasodilatory and hypoglycaemic effects of two pyrano-isoflavone extractives from <i>Eriosema kraussianum</i> N. E. Br. [Fabaceae] rootstock in experimental rat models. 2006 , 67, 610-7		26
275	Impairment of endothelium- and nerve-mediated relaxation responses in the cavernosal smooth muscle of experimentally diabetic rabbits: role of weight loss and duration of diabetes. 2006 , 373, 71-8		10
274	Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. 2006 , 3, 253-64; discussion 264-5, author reply 265-6		113
273	Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. 2006 , 3, 883-891		56
272	Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. 2006 , 3, 1037-1049		44
271	Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. 2006 , 48, 128-33		45
270	Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. 2006 , 20, 539-41		19

269	Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction. 2007 , 23, 3189-98		10
268	Correlations between increased erection hardness and improvements in emotional well-being and satisfaction outcomes in men treated with sildenafil citrate for erectile dysfunction. 2007 , 19, 398-406		20
267	Sildenafil reduces bother associated with erectile dysfunction: pooled analysis of five randomized, double-blind trials. 2007 , 19, 584-90		5
266	Sildenafil in the treatment of erectile dysfunction. 2007 , 3, 295-303		2
265	Chronic sildenafil in men with diabetes and erectile dysfunction. 2007 , 3, 451-64		24
264	Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. <i>American Journal of the Medical Sciences</i> , 2007 , 334, 466-80	2.2	14
263	Sexual sequelae of general medical disorders. 2007 , 369, 409-24		213
262	Sexual dysfunction in men and women with endocrine disorders. 2007 , 369, 597-611		220
261	Traitement médicamenteux du diabète de type 2 recommandation de bonne pratique. 2007 , 33, S26-S105		5
260	Phosphodiesterase type 5 inhibitors: state of the therapeutic class. 2007 , 34, 507-15, vi		23
259	Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. 2007 , CD002187		50
258	Diabetes and sexual dysfunction: results from the Olmsted County study of urinary symptoms and health status among men. <i>Journal of Urology</i> , 2007 , 177, 1438-42	2.5	72
257	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. 2007 , 19, 281-95		33
256	Analysis of the efficacy and safety of sildenafil citrate in the geriatric population. 2007 , 100, 117-21		17
255	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. 2007 , 61, 1547-54		20
254	Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. 2007 , 52, 1768-74		57
253	Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. 2007 , 4, 166-175		36
252	Phosphodiesterase type 5 inhibitors and endothelial function. 2007 , 4, 157-162		1

251	Hypoglycaemic effect of <i>Eriosema kraussianum</i> N. E. Br. [Fabaceae] rootstock hydro-alcohol extract in rats. 2007 , 61, 244-250	4
250	Management of erectile dysfunction in diabetes: an update for 2008. 2008 , 8, 437-43	8
249	Calcium dobesilate for the treatment of erectile dysfunction in men with diabetes mellitus. 2008 , 103, 360-6	1
248	Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. 2008 , 102, 39-43	53
247	Type 2 diabetes-associated androgen alteration in patients with erectile dysfunction. 2008 , 31, 602-8	26
246	Expression and distribution of cyclic GMP-dependent protein kinase-1 isoforms in human penile erectile tissue. 2008 , 5, 536-43	14
245	Efficient gene expression system using the RTP801 promoter in the corpus cavernosum of high-cholesterol diet-induced erectile dysfunction rats for gene therapy. 2008 , 5, 1355-64	14
244	Sexual counseling in elderly couples. 2008 , 5, 2027-43	33
243	Erectile dysfunction in diabetic males: Plausible mechanisms and management strategies. 2008 , 2, 81-86	2
242	Sexual satisfaction and cardiovascular disease: the Women's Health Initiative. 2008 , 121, 295-301	37
241	[Non-pharmacological interventions for the treatment of erectile dysfunction in adult men: systematic review]. 2008 , 18, 64-9	2
240	Treatment strategies for diabetic patients suffering from erectile dysfunction. 2008 , 9, 257-66	15
239	Prognostic factors predicting successful response to sildenafil after radical cystoprostatectomy. 2008 , 42, 110-5	6
238	Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. 2008 , 17, 855-64	16
237	Erectile Dysfunction in Diabetes. 2008 , 391-398	
236	Pharmacotherapy for erectile dysfunction. 2008 , 17, 679-90	16
235	Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors. 2008 , 30, 130-4	16
234	Endocrinology. 2008 , 127-162	1

233	Relaxation of rabbit corpus cavernosum smooth muscle and aortic vascular endothelium induced by new nitric oxide donor substances of the nitrosyl-ruthenium complex. 2008 , 34, 638-45; discussion 645-6		13
232	Helping people with sexual problems. 2009 , 343-380		2
231	A multicenter, randomized, open-labeled, parallel group trial of sildenafil in alcohol-associated erectile dysfunction: the impact on psychosocial outcomes. 2009 , 6, 2510-25		3
230	Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?. 2009 , 32 Suppl 2, S420-2		7
229	Superoxide dismutase analog (Tempol: 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment restores erectile function in diabetes-induced impotence. 2009 , 21, 348-55		15
228	Losartan, an Angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats. 2009 , 6, 696-707		27
227	The novel antioxidant, AC3056 (2,6-di- <i>t</i> -butyl-4-((dimethyl-4-methoxyphenylsilyl)methoxy)phenol), reverses erectile dysfunction in diabetic rats and improves NO-mediated responses in penile tissue from diabetic men. 2009 , 6, 373-87		27
226	Review type 2 diabetes mellitus and erectile dysfunction. 2009 , 6, 916-926		54
225	Erectile dysfunction in diabetes mellitus. 2009 , 6, 1232-47		247
224	A critical appraisal of erectile function in animal models of diabetes mellitus. 2009 , 32, 93-114		23
223	Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. <i>Asian Journal of Andrology</i> , 2009 , 11, 629-37	2.8	1
222	The burden and extent of comorbid conditions in patients with erectile dysfunction. 2009 , 63, 1205-13		42
221	Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a double-blind, randomized and placebo-controlled study. 2009 , 104, 376-83		15
220	Is type 2 diabetes mellitus a cause of severe erectile dysfunction in patients with metabolic syndrome?. 2009 , 74, 561-4		13
219	Androgen pattern in patients with type 2 diabetes-associated erectile dysfunction: impact of metabolic control. 2009 , 74, 552-9		18
218	Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. 2009 , 74, 831-836.e8		34
217	Diabetes, obesity and erectile dysfunction: field overview and research priorities. <i>Journal of Urology</i> , 2009 , 182, S45-50	2.5	45
216	Sexualidad en la edad geriátrica: disfunción eréctil, sintomatología urinaria del tracto inferior y posibilidades de tratamiento. 2009 , 7, 106-111		0

215	Erectile dysfunction and diabetes mellitus. 2009 , 4, 114-122	14
214	[Etiology and management of erectile dysfunction in patients with diabetes mellitus]. 2009 , 19, 364-71	7
213	Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction. 2010 , 135-172	
212	Treatment of erectile dysfunction in the older diabetic patient. 2010 , 6, 9-29	
211	Approach and evaluation of neurogenic bladder dysfunction. 61-78	4
210	Sexual problems in diabetes. 2010 , 38, 661-662	
209	Sildenafil and glyceryl trinitrate reduce tactile allodynia in streptozotocin-injected rats. 2010 , 631, 17-23	6
208	Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. 2010 , 7, 156-65	102
207	Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction. 2010 , 7, 224-33	41
206	Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. 2010 , 7, 244-55	18
205	Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. 2010 , 7, 758-68	92
204	Pharmacotherapy for erectile dysfunction. 2010 , 7, 524-40	132
203	The impact of sexual orientation on sexuality and sexual practices in North American medical students. 2010 , 7, 2391-400	58
202	Chronic administration of sildenafil modified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction. 2010 , 7, 3868-78	34
201	Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. 2010 , 7, 3635-46	35
200	Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. 2010 , 64, 848-57	158
199	Evaluation of erectile dysfunction and associated cardiovascular risk using structured questionnaires in Chinese type 2 diabetic men. 2010 , 33, 853-60	19
198	Evaluation and management of neurogenic sexual dysfunction. 153-166	2

- 197 Vardenafil in Erectile Dysfunction: The Evidence of Its Therapeutic Value. **2010**, 2, CMT.S3787
- 196 Experimental model of human corpus cavernosum smooth muscle relaxation. **2010**, 36, 490-4; discussion 495-6 3
- 195 Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. **2010**, 22, 325-35 21
- 194 Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. **2010**, 22, 310-7 29
- 193 Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. **2010**, 22, 51-60 48
- 192 Gene therapy as future treatment of erectile dysfunction. **2010**, 10, 1305-14 24
- 191 Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. **2010**, 19, 1427-37 61
- 190 Persistencia y cambio de tratamiento para la disfunción eréctil en pacientes españoles: estudio EDOS. **2010**, 8, 6-13 4
- 189 European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. **2011**, 37 Suppl 3, S27-38 204
- 188 Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism. **2011**, 52, 725-35 6
- 187 Promoting the sexual health of the older couple. **2011**, 7, 681-693
- 186 Poly(ADP-Ribose) polymerase inhibition improves erectile function in diabetic rats. **2011**, 8, 1002-14 15
- 185 Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. **2011**, 8, 851-64 9
- 184 Erectile response to type 5 phosphodiesterase inhibitor could be preserved with the addition of simvastatin to conventional insulin treatment in rat model of diabetes. **2011**, 34, e468-74 9
- 183 Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. **2011**, 60, 969-80 60
- 182 Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats. **2012**, 24, 114-21 9
- 181 Disorders of Male Sexual Desire. **2012**, 1-31
- 180 Considerations in the design of clinical trials for erectile dysfunction. **2012**, 2, 733-745 0

179	Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. 2012 , 38, 1-13		85
178	Intracavernous delivery of freshly isolated stromal vascular fraction rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. 2012 , 9, 3051-65		27
177	Role of hydrogen sulfide in the physiology of penile erection. 2012 , 33, 529-35		19
176	Screening for Rho-kinase 2 inhibitory potential of Indian medicinal plants used in management of erectile dysfunction. 2012 , 144, 483-9		25
175	Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. 2012 , 87, 843-52		63
174	Male sexual dysfunction and infertility associated with neurological disorders. <i>Asian Journal of Andrology</i> , 2012 , 14, 61-8	2.8	78
173	Differential expression of nerve injury-induced protein 1 (ninjurin 1) in in vivo and in vitro models for diabetic erectile dysfunction. 2012 , 53, 636-42		4
172	Identification of mechanisms involved in the relaxation of rabbit cavernous smooth muscle by a new nitric oxide donor ruthenium compound. 2012 , 38, 687-94		3
171	A review of the relationships between extreme obesity, quality of life, and sexual function. 2012 , 22, 668-76		98
170	Neurotrophic effect of bone marrow mesenchymal stem cells for erectile dysfunction in diabetic rats. 2012 , 35, 601-7		57
169	Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. 2012 , 9, 970-85		46
168	Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. 2012 , 9, 1134-48		76
167	Propionyl-L-carnitine, L-arginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction. 2012 , 44 Suppl 1, 600-4		15
166	Inhibition of sympathetic neuroeffector transmission in human corpus cavernosum. 2012 , 110, 856-62		8
165	Nitric oxide-releasing polymeric microspheres improve diabetes-related erectile dysfunction. 2013 , 10, 1915-25		8
164	Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. 2013 , 10, 551-61		29
163	The influence of ethanol intake on RhoA/Rho kinase signaling pathway in corpus cavernosum of OLETF rats. 2013 , 45, 429-38		3
162	Dysfonction Erectile. 2013 , 37, S648		

161	Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. 2013 , 11, 222-9	24
160	Reproductive sequelae of diabetes in male patients. 2013 , 42, 899-914	15
159	Diabetic autonomic neuropathy. 2013 , 117, 279-94	77
158	Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus. 2013 , 10, 362-9	10
157	SOP conservative (medical and mechanical) treatment of erectile dysfunction. 2013 , 10, 130-71	117
156	Erectile dysfunction. 2013 , 37 Suppl 1, S150-2	6
155	Dysfonction Erectile. 2013 , 37, S528-S530	
154	Erectile Dysfunction. 2013 , 37, S337	
153	Ca ²⁺ -activated K ⁺ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. 2013 , 169, 449-61	34
152	Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. 2013 , 63, 902-12	157
151	Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus. 2013 , 10, 1146-50	20
150	Impotence. 2013 , 379-388	
149	Erectile dysfunction - an update of current practice and future strategies. 2013 , 6, 210-219	3
148	Sildenafil: two decades of benefits or risks?. 2013 , 16, 85-91	19
147	Sildenafil increases sympathetically mediated vascular tone in humans. 2013 , 26, 762-9	12
146	Diabetes and sexual dysfunction: current perspectives. 2014 , 7, 95-105	108
145	Black tea extract and its thearubigins relieve the sildenafil-induced delayed gut motility in mice: a possible role of nitric oxide. 2014 , 28, 1687-91	9
144	Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. 2014 , 21, 1263-7	19

143	Total testosterone levels and the effect of sildenafil on type 2 diabetics with erectile dysfunction. 2014 , 29, 46-50		3
142	Neurologic complications of diabetes. 2014 , 14, 457		12
141	Sexual dysfunction in diabetes. 2014 , 126, 223-32		33
140	Transplantation KCNMA1 modified bone marrow-mesenchymal stem cell therapy for diabetes mellitus-induced erectile dysfunction. 2014 , 46, 479-86		28
139	Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. 2014 , 11, 1182-92		17
138	How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. 2014 , 14, 545		34
137	Treatment strategies for diabetic patients suffering from erectile dysfunction: an update. 2014 , 15, 1827-36		21
136	Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. 2015 , 51, 22-36		5
135	Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction. <i>Asian Journal of Andrology</i> , 2015 , 17, 143-8	2.8	6
134	Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions. 2015 , 12, 63-83		40
133	Optimizing in vivo gene transfer into mouse corpus cavernosum by use of surface electroporation. 2015 , 56, 197-204		2
132	Hydrogen Sulfide and Urogenital Tract. 2015 , 230, 111-36		15
131	Erectile dysfunction and its management in patients with diabetes mellitus. 2015 , 16, 213		19
130	ROS activates JNK-mediated autophagy to counteract apoptosis in mouse mesenchymal stem cells in vitro. 2015 , 36, 1473-9		60
129	Stem cell treatment of erectile dysfunction. 2015 , 82-83, 137-44		41
128	Sexual problems in diabetes. 2015 , 43, 38-40		2
127	Complications of Diabetes Mellitus. 2016 , 1484-1581		11
126	Sexual Dysfunction in Men and Women. 2016 , 785-830		1

125	Molecular and functional characterization of Kv 7 channels in penile arteries and corpus cavernosum of healthy and metabolic syndrome rats. 2016 , 173, 1478-90		21
124	Sexual Function in Men and Women with Diabetes. 2016 , 716-730		
123	Effect of phosphodiesterase-5 inhibitors on glycemic control in person with type 2 diabetes mellitus: A systematic review and meta-analysis. 2016 , 6, 50-55		6
122	Intracavernous delivery of clonal mesenchymal stem cells rescues erectile function in the streptozotocin-induced diabetic mouse. <i>Andrology</i> , 2016 , 4, 172-84	4.2	21
121	Management of erectile dysfunction in men with diabetes. 2016 , 210-219		
120	Management of erectile dysfunction in neurological patients. 2016 , 220-228		1
119	Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). 2016 , 13, 465-88		110
118	Female Sexual Dysfunction: Is It a Treatable Disease?. 2016 , 17, 28		5
117	Antioxidant Potential and Ability of Phloroglucinol to Decrease Formation of Advanced Glycation End Products Increase Efficacy of Sildenafil in Diabetes-Induced Sexual Dysfunction of Rats. 2016 , 4, e104-12		23
116	Diabetes Mellitus. 2016 , 920-933.e5		
115	Resveratrol reverses diabetes-related decrement in sildenafil-induced relaxation of corpus cavernosum in aged rats. 2017 , 29, 345-351		2
114	Treatment response to sildenafil in men with erectile dysfunction relative to concomitant comorbidities and age. 2017 , 71, e12939		2
113	Improvement in erectile function in a rat model of high cholesterol diet-induced atherosclerosis by atorvastatin in a manner that is independent of its lipid-lowering property. 2017 , 49, e12789		3
112	Gonadal dysfunction in chronic kidney disease. 2017 , 18, 117-130		45
111	Involvement of DDAH/ADMA/NOS/cGMP and COX-2/PTGIS/cAMP Pathways in Human Tissue Kallikrein 1 Protecting Erectile Function in Aged Rats. <i>PLoS ONE</i> , 2017 , 12, e0170427	3.7	4
110	Sexual Dysfunction and Hypogonadism in Men With Diabetes. 2018 , 42 Suppl 1, S228-S233		11
109	Topically Applied Curcumin-Loaded Nanoparticles Treat Erectile Dysfunction in a Rat Model of Type-2 Diabetes. 2018 , 15, 645-653		12
108	Erectile Dysfunction. 2018 , 623-629.e2		

107	Engineered Mesenchymal Stem Cells Expressing Stromal Cell-derived Factor-1 Improve Erectile Dysfunction in Streptozotocin-Induced Diabetic Rats. 2018 , 19,	22
106	Efficient Promotion of Autophagy and Angiogenesis Using Mesenchymal Stem Cell Therapy Enhanced by the Low-Energy Shock Waves in the Treatment of Erectile Dysfunction. 2018 , 2018, 1302672	45
105	Human tissue kallikrein 1 ameliorates erectile function via modulation of macroautophagy in aged transgenic rats. <i>Andrology</i> , 2018 , 6, 766-774	4.2 7
104	Endothelial colony forming cells from human umbilical cord blood improved severe erectile dysfunction in obese type II diabetic rats. <i>Life Sciences</i> , 2018 , 207, 272-283	6.8 3
103	Sexual Dysfunction in Men and Women With Chronic Kidney Disease. 2018 , 277-290	
102	Sexual complications of penile fracture in men who have sex with men. 2018 , 44, 550-554	6
101	Management of erectile dysfunction. 2018 , 545-554	
100	Pharmacotherapy for erectile dysfunction in diabetic males. 2018 , 19, 1345-1356	0
99	An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction. 2019 , 16, 1541-1546	3
98	. Leaf Extract Improves Erectile Dysfunction in Streptozotocin-Induced Diabetic Rats by Protecting Endothelial Function and Ameliorating Hypothalamic-Pituitary-Gonadal Axis Function. 2019 , 2019, 1782953	8
97	Erectile Dysfunction Is Highly Prevalent in Men With Newly Diagnosed Inflammatory Bowel Disease. 2019 , 25, 1408-1416	12
96	Erectile Dysfunction and Premature Ejaculation in Homosexual and Heterosexual Men: A Systematic Review and Meta-Analysis of Comparative Studies. 2019 , 16, 624-632	17
95	Erectile Dysfunction. 2019 , 21-32	
94	Physical activity counteracts metabolic syndrome-induced hypogonadotropic hypogonadism and erectile dysfunction in the rabbit. 2019 , 316, E519-E535	27
93	Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials. 2019 , 37, 1061-1074	14
92	The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. 2019 , 7, 115-128	53
91	Female Sexual Dysfunction: A Systematic Review of Outcomes Across Various Treatment Modalities. 2019 , 7, 223-250	32
90	A Small Group Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Daily Pentoxifylline in the Management of Patients With Erectile Dysfunction with Suboptimal Treatment Response to Sildenafil. 2020 , 8, 14-20	4

89	Review of a Potential Novel Approach for Erectile Dysfunction: Light-Controllable Nitric Oxide Donors and Nanoformulations. 2020 , 8, 297-302		7
88	Role of Phosphodiesterase in the Biology and Pathology of Diabetes. 2020 , 21,		4
87	Commentary RE: The International Index of Erectile Function (IIEF): A Multidimensional Scale for Assessment of Erectile Dysfunction. 2020 , 145, 308-309		0
86	Intracavernous delivery of Dickkopf3 gene or peptide rescues erectile function through enhanced cavernous angiogenesis in the diabetic mouse. <i>Andrology</i> , 2020 , 8, 1387-1397	4.2	1
85	Baicalein Alleviates Erectile Dysfunction Associated With Streptozotocin-Induced Type I Diabetes by Ameliorating Endothelial Nitric Oxide Synthase Dysfunction, Inhibiting Oxidative Stress and Fibrosis. 2020 , 17, 1434-1447		5
84	Effects of "metabolic memory" on erectile function in diabetic men: A retrospective case-control study. <i>Andrology</i> , 2021 , 9, 288-296	4.2	1
83	Erectile Dysfunction: an Integrative Approach.		
82	The Genus (Fabaceae): From the Ethnopharmacology to an Evidence-Based Phytotherapeutic Perspective?. <i>Frontiers in Pharmacology</i> , 2021 , 12, 641225	5.6	3
81	Erectile Dysfunction in Diabetes Mellitus.		1
80	Sexual Function in Men and Woman with Diabetes. 743-759		1
79	Genitourinary Complications. 2007 , 453-472		2
78	Sexual aspects of medical practice. 2009 , 381-412		5
77	Rehabilitation Management of Neuropathies. 2005 , 2621-2636		1
76	Sexual Dysfunction in Men and Women. 2011 , 778-816		2
75	Complications of Diabetes Mellitus. 2011 , 1462-1551		7
74	The effect of diet-induced insulin resistance on DNA methylation of the androgen receptor promoter in the penile cavernosal smooth muscle of mice. <i>Asian Journal of Andrology</i> , 2013 , 15, 487-91	2.8	11
73	Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy. <i>American Journal of the Medical Sciences</i> , 2000 , 320, 69-71	2.2	30
72	Immunization associated with erectile dysfunction based on cross-sectional and genetic analyses. <i>PLoS ONE</i> , 2014 , 9, e111269	3.7	9

71	Sexual dysfunction in uremia. <i>Journal of the American Society of Nephrology: JASN</i> , 1999 , 10, 1381-8	12.7	204
70	The GAY MEn Sex Studies: design of an online registration of sexual behaviour of men having sex with men and preliminary results (GAMESSS-study). <i>Central European Journal of Public Health</i> , 2013 , 21, 48-53	1.2	7
69	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 403-14	4	36
68	Reduced corporal fibrosis to protect erectile function by inhibiting the Rho-kinase/LIM-kinase/cofilin pathway in the aged transgenic rat harboring human tissue kallikrein 1. <i>Asian Journal of Andrology</i> , 2017 , 19, 67-72	2.8	20
67	Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015 , 19, 451-61	1.7	24
66	Combination of stromal vascular fraction and gene therapy improves long-term therapeutic efficacy for diabetes-induced erectile dysfunction. <i>Asian Journal of Andrology</i> , 2018 , 20, 465-472	2.8	3
65	A meta-analysis on efficacy and tolerability of sildenafil for erectile dysfunction in patients with diabetes mellitus. <i>Indian Journal of Sexually Transmitted Diseases and AIDS</i> , 2018 , 39, 1-6	0.5	4
64	The Influence of Treatment-emergent Adverse Reactions on Selecting Phosphodiesterase Type 5 Inhibitors. <i>Korean Journal of Urology</i> , 2006 , 47, 272		1
63	Sildenafil. <i>Practical Diabetes</i> , 2021 , 38, 41-43	0.7	
62	The potential role of C-peptide in sexual and reproductive functions in type 1 diabetes mellitus: An update. <i>Current Diabetes Reviews</i> , 2021 ,	2.7	
61	REDUCTION OF ENDOTHELIAL AND SMOOTH MUSCLE DENSITY IN THE CORPORA CAVERNOSA OF THE STREPTOZOTOCIN INDUCED DIABETIC RAT. <i>Journal of Urology</i> , 2000 , 1807-1811	2.5	1
60	CORPOREAL STRUCTURAL AND VASCULAR MICRO ARCHITECTURE WITH X-RAY MICRO COMPUTERIZED TOMOGRAPHY IN NORMAL AND DIABETIC RABBITS: HISTOPATHOLOGICAL CORRELATION. <i>Journal of Urology</i> , 2001 , 1776-1782	2.5	
59	LONG-TERM EFFICACY OF SILDENAFIL AND TACHYPHYLAXIS EFFECT. <i>Journal of Urology</i> , 2001 , 927-931	2.5	1
58	Anatomie, Physiologie, Pathophysiologie. 2002 , 13-101		
57	Therapie. 2002 , 129-246		
56	Management of impotence in diabetes. 2002 , 69-107		
55	Diabetes Mellitus. 191		1
54	Sexualität. 2004 , 259-298		

- 53 Sexual dysfunction in the dialysis patient. **2004**, 1333-1342
- 52 Management of Erectile Dysfunction. **2004**, 65-88
- 51 Male Sexual Dysfunction in Diabetes Mellitus. **2004**, 417-437
- 50 Oral Type 5 Phosphodiesterase Therapy for Male and Female Sexual Dysfunction. **2004**, 107-119
- 49 Autonomic Neuropathy.
- 48 Middle adulthood: ages 40-54. **2004**, 92-113
- 47 Erectile Dysfunction. **2005**, 193-223
- 46 Erectile Dysfunction. **2006**, 395-410
- 45 Diabetes mellitus and sexual dysfunction. **2007**, 53-73
- 44 Section I: Psychological Interventions. **2007**, 373-376
- 43 Diabetic Peripheral Neuropathy and Sexual Dysfunction. **2007**, 277-312
- 42 Treatment of Erectile Dysfunction in Chronic Kidney Disease. **2008**, 783-790
- 41 Impotence. **2009**, 385-393
- 40 Sexual Dysfunction in Men and Women with Chronic Kidney Disease. **2009**, 429-440
- 39 Specific features of urogenital disorders in patients with diabetes mellitus. *Diabetes Mellitus*, **2009**, 12, 40-45 1.6 3
- 38 Male Sexual Dysfunction in Diabetes Mellitus. **2010**, 401-417
- 37 Diabetes Mellitus: Neuropathy. **2010**, 984-998 1
- 36 Management of Erectile Dysfunction. 134-145

- 35 Oral Therapy for Erectile Dysfunction. **2011**, 93-106 0
- 34 Erectile Dysfunction. **2012**, 560-566.e2
- 33 Medikamente zur Behandlung sexueller Funktionsstörungen. **2012**, 751-763
- 32 Diabetische Folgeerkrankungen. **2014**, 239-296
- 31 Vascular Erectile Dysfunction. **2014**, 1-39
- 30 The management of erectile dysfunction associated with diabetes. *Sexual Dysfunction*, **1998**, 1, 113-118
- 29 . **2014**, 12,
- 28 Vascular Erectile Dysfunction. **2015**, 3887-3915
- 27 Male Sexual Dysfunction in Diabetes Mellitus. **2016**, 1-22
- 26 Male Sexual Dysfunction in Diabetes Mellitus. **2017**, 491-512 1
- 25 Treatment of Erectile Disorder. **2017**, 187-201
- 24 Sex and Pharmacological Sexual Enhancement. **2017**, 387-411
- 23 Comparing the Effect of Walking and Yoga on Clinical and Laboratory Parameters in Men with Type II Diabetes: A Randomized Controlled Clinical Trial. *Jundishapur Journal of Chronic Disease Care*, **2020**, 9, 1.4
- 22 Erectile dysfunction in diabetes mellitus: A review. *Journal of Diabetology*, **2020**, 11, 1 0.8 1
- 21 Aphrodisiac Potentials of Pausinystalia yohimbe (K. Schum.) Pierre ex Beille Methanol Root Extract in Male Wistar Rats. *Journal of Integrative Nephrology and Andrology*, **2020**, 7, 47 0.1 1
- 20 Dysfunction of Sexual and Accessory Sex Organs. **2020**, 91-120
- 19 Medikamente zur Behandlung sexueller Funktionsstörungen. **2008**, 687-699
- 18 Use of Stem Cells in the Treatment of Erectile Dysfunction. **2021**, 347-365

17	Systematic review of randomised controlled trials of sildenafil (Viagra) in the treatment of male erectile dysfunction. <i>British Journal of General Practice</i> , 2001 , 51, 1004-12	1.6	19
16	Future strategies for treating erectile dysfunction. <i>Reviews in Urology</i> , 2002 , 4 Suppl 3, S48-53	1	1
15	Four-year review of sildenafil citrate. <i>Reviews in Urology</i> , 2002 , 4 Suppl 3, S26-38	1	9
14	Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. <i>Reviews in Urology</i> , 2003 , 5 Suppl 7, S9-S20	1	1
13	Erectile dysfunction in patients with cardiovascular disease. <i>Netherlands Heart Journal</i> , 2006 , 14, 139-146.2		
12	Pharmacotherapy of sexual dysfunctions : current status. <i>Indian Journal of Psychiatry</i> , 2004 , 46, 213-20	2.2	5
11	African traditional medicines for erectile dysfunction: elusive dream or imminent reality?. <i>Cardiovascular Journal of Africa</i> , 2007 , 18, 213-5	0.7	4
10	Erectile Dysfunction and Other Sexual Activity Dysfunctions among Saudi Type 2 Diabetic Patients. <i>International Journal of Health Sciences</i> , 2014 , 8, 347-59	1.1	6
9	Beneficial Extracardiac Effects of Cardiovascular Medications. <i>Current Cardiology Reviews</i> , 2021 ,	2.4	1
8	In vitro inhibition of phosphodiesterase type 4 enhances rat corpus cavernosum nerve-mediated relaxation induced by gasotransmitters.. <i>Life Sciences</i> , 2022 , 296, 120432	6.8	
7	Efficacy Evaluation of Plant Products in the Treatment of Erectile Dysfunction Related to Diabetes.. <i>Nutrients</i> , 2021 , 13,	6.7	1
6	Diagnosis and Management of Diabetic Autonomic Neuropathy. <i>Comprehensive Therapy</i> , 2003 , 29, 130-145		
5	Synthesis, Structural, Biocomputational Modeling and Antifungal Activity of Novel Armed pyrazoles. <i>Journal of Molecular Structure</i> , 2022 , 133156	3.4	0
4	MYPT1 reduction is a pathogenic factor of erectile dysfunction. <i>Communications Biology</i> , 2022 , 5,	6.7	0
3	Urologic complications in diabetes. 2022 , 36, 108288		0
2	Urogenital dysfunction following neurotrauma. 2022 , 35, 753-760		0
1	Combination of traditional Chinese medicine and PDE5i for diabetic erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials.		0